S-5751 is an antagonist of the prostaglandin D₂ (PGD₂) receptor DP₁ (K_i = 1.6 nM) that shows at least 20-fold selectivity over receptors for thromboxane and prostacyclin, as well as the PGE₂ receptor EP₂.^1,2 Orally administered S-5751 blocks PGD₂-induced plasma exudation in the conjunctiva (ED₅₀ = 0.099 mg/kg) and suppresses antigen-induced allergic responses in guinea pigs.¹ S-5751 has been used to distinguish signaling of PGD₂ through its two receptors, DP₁ and DP₂ (also known as CRTH2).³

≥95%